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Available online xxxxBackground: Takotsubo syndrome (TT) and myocardial infarction (MI) share numerous similarities in clinical
presentation, ECG modiﬁcations and biomarker elevation. We sought to determine whether the ratio of high-
sensitivity cardiac troponin T (hs-TnT) to the myocardial fraction of creatine kinase (CKMB) could be a potent
discriminator between TT and MI patients.
Methods:We separately present analysis of data from retrospective ﬁles and prospectively recruited patients
presenting with TT (35 retrospective and 42 prospective), NSTEMI (48 retrospective and 75 prospective) and
STEMI (20 retrospective and 39 prospective). We compared ratios of hs-TnT to CKMB on admission to the
hospital between TT, NSTEMI and STEMI patients. Receiver operating characteristic (ROC) curves were analysed
to determine optimal cut-off values.
Results: On admission, hs-TnT/CKMB ratio was signiﬁcantly higher in TT patients than in NSTEMI and STEMI
patients in both the retrospective phase (median and interquartile range, TT 0.024 [0.018–0.047] vs NSTEMI
0.009 [0.006–0.022], p b 0.0001; TT vs STEMI 0.011 [0.006–0.016], p = 0.0002) and the prospective cohort
(median and interquartile range, TT 0.032 [0.018–0.040] vs NSTEMI 0.009 [0.006–0.015], p b 0.0001; TT vs
STEMI 0.009 [0.005–0.017], p b 0.0001). A cut-off hs-TnT/CKMB ratio of 0.015 distinguished TT from MI with a
sensitivity of 85.7% and a speciﬁcity of 67.6% (AUC 0.796; 95%CI: 0.71–0.89) in the retrospective phase. In the
prospective phase, a ratio of 0.017 distinguished TT from MI with a sensitivity of 83.3% and a speciﬁcity of
78.1% (AUC 0.88; 95%CI: 0.83–0.94).
Conclusion: hs-TnT/CKMB ratio is a novel, readily available parameter that could be used alongside clinical risk
scores, other biomarkers and ECG ﬁndings to discriminate between TT and MI.





Takotsubo syndrome (TT) is an increasingly diagnosed condition
[1–3] and our understanding of its clinical proﬁle has evolved. Straying
away from the initial description [4,5] of ST elevation following an acute
psychological stress, different electrocardiographic (ECG) presentations
and other triggers, if any, are now more commonly reported [6]. Fur-
thermore, bystander coronary artery disease is present in up to 15% of
reported cases [6–8]. Thus, clinicians are frequently confronted with
challenging caseswhere diagnosis is equivocal especially when imaging
of the left ventricle is performed late in the clinical course. Moreover,
many authors now suggest that invasive imagingmay not be necessary
in patients presenting without ST segment elevation [9,10]. In this set-
ting, much research has been conducted to ﬁnd discriminatory markers
between acute coronary syndromes, especially ST-segment elevationeliability and freedom from bias
io of high-sensitivity troponi
7myocardial infarction (STEMI), and TT as appropriate diagnosis has
important implications with regards to management and prognosis.
This study was inspired by a simple clinical observation: we know
that patients with TT present with smaller elevations in troponin and
creatine kinase than STEMI [11,12]. However, as observed by others,
the elevation in creatine kinase [7,13], more speciﬁcally its myocardial
fraction (CKMB), is smaller in comparison to the elevation in troponin
than inmyocardial infarction (MI). In other words, the ratio of troponin
to CKMB seems higher in TT than in MI. Therefore, after gathering our
retrospective data, we designed a single centre prospective study to
test whether the ratio of high-sensitivity troponin T (hs-TnT) to CKMB
could be used as a discriminatory marker between these two entities.
In this report, we present both our retrospective and prospective data.2. Methods
This study was conducted at the Liège University Hospital (CHU de
Liège), Belgium, which accepts referrals for acute coronary syndromes
from other regional hospitals.n to creatine kinase-MB in takotsubo syndrome, Int J Cardiol (2017),
2 C. Pirlet et al. / International Journal of Cardiology xxx (2017) xxx–xxxTT patients had to have been hospitalized for the diagnosis of TT and
had to have undergone coronary angiography and left ventriculography.
Diagnosis of TT was established according to recently revised criteria
[6]: i). Transient regional wall motion abnormalities (WMA) extending
beyond a single epicardial vascular distribution. ii). Absence of culprit cor-
onary artery disease (thrombus, severe stenosis, spontaneous dissection)
or other pathological conditions to explain the pattern of temporary left
ventricular dysfunction. iii). New and reversible ECG abnormalities. iv).
Positive but relatively small elevation in cardiac troponin. Follow-up at
least three months after the index hospitalization conﬁrming normalisa-
tion of wall motion abnormalities and left ventricular systolic function
was obtained through review of medical ﬁles and by telephone contact
with the cardiologist of the patient. Cardiac magnetic resonance imaging
(MRI) during the index hospitalization to exclude myocarditis was
performed at the discretion of the treating physician. In accordance
with recent literature, many patients beneﬁted from cardiac MRI three
months after the index event to conﬁrm regression of WMA and to
exclude the presence of late gadolinium enhancement due to other
causes such as MI or myocarditis. However, as this study was purely
observational, cardiac MRI was not part of the study protocol.
ConcerningMI patients, this study was limited to type 1 MI patients
[14] conﬁrmed by coronary angiography presenting within 36 h of
symptom onset. These patients were classiﬁed as STEMI and NSTEMI
patients according to their initial ECG presentation. Only those with
biomarker elevations prior to percutaneous coronary intervention
(PCI) were considered and laboratory data after PCI was discarded in
order to observe only the natural course of these cardiac biomarkers.
Exclusion criteria included signiﬁcant kidney disease (deﬁned
arbitrarily in accordancewith other similar studies [10] by a glomerular
ﬁltration rate (GFR) inferior to 35 mL/min/1.73 m2 according to the
MDRD formula) and cardiac/muscle biomarker elevation due to other
causes.
Retrospective datawere extracted from the digitalmedical ﬁles from
November 2011 to April 2014. High-sensitivity troponin T assays were
available at Liège University Hospital as from November 2011. All
female patients with type 1 MI without ST segment elevation were
deemed suitable for inclusion. To limit the NSTEMI and STEMI sample
sizes, the samples of male patients were arbitrarily limited to a random
population totalling 25% of the NSTEMI and STEMI cohorts. This seemed
logical as the incidence of TT is believed to be higher in women. Data
from all eligible patients were collected.
Prospective inclusion of patients started in April 2014 and ended in
December 2016. To limit the NSTEMI sample size without introducing
selection bias, these patientswere recruited only amongst those present
in the coronary unit on one speciﬁc day of the week.
The studywas approved by the institutional ethics review committee
and compliedwith the principles of theHelsinki Declaration. All prospec-
tively recruited patients provided informed consent.
hs-TnT and CKMBwere simultaneouslymeasured on admission and
then every 6 h within the ﬁrst 24 h according to the institutional proto-
col. For all patients, relevant data included age at the index event,
gender, smoking status, beta-blocker therapy, GFR and up to ﬁve simulta-
neous hs-TnT and CKMB measurements. For TT patients, ECG presenta-
tion, history of vascular or coronary disease, ballooning pattern and
recurrence were also recorded. In the prospective phase, NT-proBNP
was also measured on admission. Logically, markers of cardiac necrosis
prior to PCI were more seldom available in STEMI patients except when
blood was drawn before primary PCI or in patients ineligible to PCI.
Analyses for hs-TnT were performed with TnT-hs (Elecsys®, Roche
diagnostics, Vilvoorde, Belgium; upper limit of normal (ULN) 14 ng/L).
NT-proBNP was measured with ProBNP II (Cobas®, Roche diagnostics,
Vilvoorde, Belgium; ULN 156 ng/L). CKMB were analysed with CK-MB
(Cobas®, Roche diagnostics, Vilvoorde, Belgium, ULN 6.2 μg/L).
In both studies (retrospective and prospective), the primary analysis
was a signiﬁcant difference in the ratio of hs-TnT to CKMB between TT,
NSTEMI and STEMI patients for the ﬁrst blood analysis recorded. ThePlease cite this article as: C. Pirlet, et al., Ratio of high-sensitivity troponi
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time when hs-TnT was at its peak. Values of troponin and CKMB were
compared between groups on admission and at the sample time when
hs-TnT was at its peak. In the prospective population, NT-proBNP and
the ratio of NT-proBNP to peak hs-TnT were also studied.
Continuous measures are described with the use of mean and stan-
dard deviation (SD) for parametric data and median and interquartile
range (IQR) for non-parametric data. Categorical datawere summarized
as frequency and percentages. Datawas checked for normal distribution
with the Shapiro-Wilk test and homogeneity of variance was conﬁrmed
with Bartlett's test/Fisher's test where appropriate. A log transformation
(base 10) was applied to laboratory measurements that did not respect
a normal distribution. The Pearson chi-square test was used for categor-
ical variables. Between group comparisons of continuous variables were
performed with a one-way analysis of variance (ANOVA) followed by
Tukey's post-hoc test if the null hypothesis was rejected. Welch's
ANOVA was used when the assumption of equal variance was not met
despite log transformation. Results were compared using the unpaired
Student t-test when only two groups (TT and MI) were compared
such as for the NT-proBNPmeasurements. Receiver operator character-
istic (ROC) curves were calculated and optimal cut-off values (Youden's
J statistic) to distinguish TT from MI were determined. The area under
the curve (AUC) and the sensitivity and speciﬁcity at the optimal cut-
off point are reported. A 2-sided probability value b0.05was considered
statistically signiﬁcant. All statistical analyses were performed with R
version 3.3.1 (The R Foundation for Statistical Computing, Vienna,
Austria) and the EZR package.
All the authorswere implicated in the design of the study and review
of the manuscript. The authors vouch for the integrity of the data.
3. Results
FromNovember 2011 toMay 2014, 35 TT patients fulﬁlled the inclu-
sion criteria for the retrospective phase of the study. These patients
were compared with 48 NSTEMI patients and 20 STEMI patients.
Thereafter, 47 TT patients were prospectively enrolled to be compared
with 75 NSTEMI patients and 39 STEMI patients who were enrolled
over the same period. There was no interruption between the retro-
spective and the prospective phases of the study. The study ended on
December 31, 2016.
In the prospective phase, two TT patients could not be included
because of incomplete biomarker proﬁles prior to referral for coronary
angiography. Lastly, three patients were excluded because of late
gadoliniumenhancement on cardiacMRI thatwas suggestive of another
disease process than TT (MI in two cases and myocarditis in the third).
Population characteristics are presented in Table 1. In line with the
usual gender distribution of TT, there were more females in the TT pop-
ulations. This was also the case in the retrospective MI populations,
reﬂecting the pre-speciﬁed sample bias to limit study population.
In both the retrospective and the prospective trials, age, smoking,
beta-blocker use and kidney function were similar albeit, as expected,
more active smokers in the MI populations.
In both trials, apical ballooning was the predominant type of WMA.
Recurrences were rare. A substantial proportion of TT patients had con-
comitant coronary artery disease. 6 patients in the retrospective phase
had a cardiac MRI in the course of their follow-up. In the prospective
phase, 18 (42.9%) patients had cardiac MRI. 4 patients (5.2%) could
not be contacted despite repeated efforts and 5 (6.5%) patients died
soon after the index event before follow-up imaging was performed.
Medians and interquartile ranges for hs-TnT, CKMB and the ratio of
hs-TnT to CKMB are displayed in Table 2 and Fig. 1. In both phases of
the trial, the ratios of hs-TnT to CKMB, on admission and at the peak
troponin value, proved to be statistically different between TT patients
and the MI subgroups. However, hs-TnT was not signiﬁcantly different
between groups in our population both on admission and at its peak
value, in the two phases of the study whereas statistically signiﬁcantn to creatine kinase-MB in takotsubo syndrome, Int J Cardiol (2017),
Table 1
Population characteristics in the retrospective and the prospective studies. GFR: glomerular ﬁltration rate. ECG: electrocardiogram. MRI: magnetic resonance imaging. min : minutes
(median).
Takotsubo NSTEMI STEMI p-Value
Retrospective – no. 35 48 20
Age – years (mean ± SD) 69.8 ± 10 69.3 ± 14.2 68.4 ± 15.2 0.923
Female sex – no. (%) 32 (91.4) 35 (72.9) 15 (75) 0.1
Tobacco use 0.78
Active smokers – no. (%) 7 (20) 13 (27.1) 6 (30)
Past smokers – no. (%) 10 (28.6) 12 (25) 3 (15)
Beta-blocker use – no. (%) 12 (34.4) 25 (52.1) 10 (50) 0.25
Kidney disease 0.888
GFR 45–60 mL/min/1.73m2 – no. (%) 5 (14.3) 9 (18.8) 5 (25)
GFR 35–45 mL/min/1.73m2 – no. (%) 3 (8.6) 4 (8.3) 1 (5)
Normal ECG – no. (%) 6 (17.1)
ST elevation – no. (%) 10 (28.6)
Q wave – no. (%) 1 (2.9)
Other modiﬁcations – no. (%) 18 (51.4)
Apical – no. (%) 28 (80)
Midventricular – no. (%) 7 (20)
Basal – no. (%) 0 (0)
Recurrence – no. (%) 1 (2.9)
Cardiac MRI – no. (%) 6 (17.1)
Coronary disease – no. (%) 8 (22.9)
Vascular disease (non-coronary) – no. (%) 3 (8.6)
Delay from symptoms to biomarker – min 1451 462 215 0.0002
Prospective – no. 42 75 39
Age – years (mean ± SD) 69.3 ± 12.3 65.2 ± 14 64.9 ± 12.7 0.23
Female sex – no. (%) 38 (90.5) 26 (34.7) 11 (28.2) b0.0001
Smoker 0.799
Current – no. (%) 12 (28.6) 30 (40) 14 (35.9)
Former – no. (%) 12 (28.6) 18 (24) 11 (28.2)
Beta-blocker use – no. (%) 19 (45.2) 30 (40) 18 (46.2) 0.771
Kidney disease 0.108
GFR 45–60 mL/min/1.73m2 – no. (%) 5 (11.9) 14 (18.7) 4 (10.3)
GFR 35–45 mL/min/1.73m2 – no. (%) 5 (11.9) 1 (1.3) 2 (5.1)
Normal ECG – no. (%) 10 (23.8)
ST elevation – no. (%) 9 (21.4)
Q wave – no. (%) 7 (16.7)
Other modiﬁcations – no. (%) 16 (38.1)
Apical – no. (%) 28 (66.7)
Midventricular – no. (%) 13 (31)
Basal – no. (%) 1 (2.3)
Recurrence – no. (%) 2 (4.7)
Cardiac MRI – no. (%) 18 (42.9)
Coronary disease – no. (%) 7 (16.7)
Vascular disease (non-coronary) – no. (%) 4 (9.5)
Delay from symptoms to biomarker – min 350.5 351.5 331.5 0.72
Table 2
Medians and interquartile ranges of hs-TnT, CKMB, NT-proBNP, hs-TnT/CKMB ratio, NT-proBNP/hs-TnT ratio in the retrospective and the prospective study. P-values of theANOVA tests (in
bold) and the Tukey post-hoc tests (after base 10 log transformation). P-values of the unpaired Student t-test (after base 10 log transformation) for the NT-proBNP and NT-proBNP/hs-TnT
ratio. CKMB: myocardial fraction of creatine kinase. hs-TnT: high-sensitivity troponin T. ANOVA: analysis of variance.
Retrospective p value Prospective p value
hs-TnT (ng/L) on admission 0.28 0.23
TT 317 [91.5–433] vs NSTEMI 218.5 [43.3–333.5] NA TT 198 [137.3–265.5] vs NSTEMI 158 [62–313] NA
TT 317 [91.5–433] vs STEMI 122.5 [70.5–248.5] NA TT 198 [137.3–265.5] vs STEMI 248 [119–700] NA
CKMB (μg/L) on admission 0.0321 b0.0001
TT 7 [3.8–12.2] vs NSTEMI 10.1 [5.2–22.7] NS TT 6.9 [5.1–10] vs NSTEMI 14.3 [6–37.7] 0.0005
TT 7 [3.8–12.2] vs STEMI 14.6 [7.3–30.9] 0.0371 TT 6.9 [5.1–10] vs STEMI 23.7 [8.5–89.2] b0.0001
Peak hs-TnT (ng/L) 0.0599 0.2158
TT 362 [175.5–699] vs NSTEMI 354.5 [222.8–705.5] NA TT 341.5 [209.5–508.8] vs NSTEMI 525 [291–868] NA
TT 362 [175.5–699] vs STEMI 158 [81.8–711] NA TT 341.5 [209.5–508.8] vs STEMI 399 [186–1732] NA
CKMB (μg/L) with peak hs-TnT 0.0074 b0.0001
TT 10.6 [5–17.9] vs NSTEMI 15.9 [9.7–42.5] 0.0068 TT 10.4 [6.9–16.6] vs NSTEMI 35.6 [16.7–59.7] 0.0001
TT 10.6 [5–17.9] vs STEMI 16.7 [8.7–39.9] NS TT 10.4 [6.9–16.6] vs STEMI 51.8 [19.8–119.2] 0.0001
hs-TnT/CKMB on admission b0.0001 b0.0001
TT 0.024 [0.018–0.047] vs NSTEMI 0.009 [0.006–0.022] b0.0001 TT 0.032 [0.018–0.04] vs NSTEMI 0.009 [0.006–0.015] b0.0001
TT 0.024 [0.018–0.047] vs STEMI 0.011 [0.006–0.016] 0.0002 TT 0.032 [0.018–0.04] vs STEMI 0.009 [0.005–0.017] b0.0001
hs-TnT/CKMB for peak hs-TnT b0.0001 b0.0001
TT 0.029 [0.023–0.045] vs NSTEMI 0.018 [0.011–0.033] 0.002 TT 0.033 [0.021–0.046] vs NSTEMI 0.018 [0.009–0.025] 0.0001
TT 0.029 [0.023–0.045] vs STEMI 0.011 [0.007–0.016] b0.001 TT 0.033 [0.021–0.046] vs STEMI 0.010 [0.007–0.018] 0.0001
NT-proBNP (ng/L) TT 3719 [1825–8171.5] vs MI 691.5 [277.3–1804.5] b0.0001
NT-proBNP/peak hs-TnT TT 7.7 [3.6–36.5] vs MI 1.2 [0.2–4.5] b0.0001
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Fig. 1. Boxplots displayingmedians and interquartile ranges for the ratios of hs-TnT to CKMB according to clinical presentation. Upper left - on admission in the retrospective study. Upper
right - at the sample time when hs-TnT is at its peak in the retrospective study. Lower left - on admission in the prospective study. Lower right - at the sample time when hs-TnT is at its
peak in the prospective study. CKMB: myocardial fraction of creatine kinase. hs-TnT: high-sensitivity troponin T.
4 C. Pirlet et al. / International Journal of Cardiology xxx (2017) xxx–xxxdifferences in CKMB values were observed on admission and at the cor-
responding peak troponin sample times. As previously reported with
conventional troponin [9,10,13,15], the ratio of NT-proBNP to hs-TnT
proved to be signiﬁcantly different (Table 2) between TT and MI
patients (NT-proBNP available in 23 and 26 patients respectively).
ROC curves (Fig. 2) and their respective AUC show that the optimal
hs-TnT/CKMB cut-off to distinguish TT from MI is on admission with a
value of 0.015 in the retrospective cohort (sensitivity 85.7%, speciﬁcity
of 67.6%, AUC 0.796; 95% CI: 0.71–0.89) and, in the prospective phase,
a ratio of 0.017 (sensitivity of 83.3%, speciﬁcity 78.1%, AUC 0.88; 95%
CI: 0.83–0.94). Surprisingly, the ROC curve of the ratio of NT-proBNP
to hs-TnT indicated a lower AUC (0.77; 95% CI: 0.63–0.91) than for the
ratio of hs-TnT/CKMB in the prospective study (Fig. 2).
4. Discussion
These two studies were a proof-of-concept work which served to
demonstrate our hypothesis that the ratio of hs-TnT troponin to CKMB
could be used as an early indicator of TT. Indeed, the ratio of hs-TnT to
CKMB was signiﬁcantly higher in TT patients than in NSTEMI and
STEMI patients on admission and later in the course of the event,
when troponin reached its peak value. In addition, at a threshold of
0.015, in the retrospective phase, and 0.017, in the prospective phase,
this ratio yields reasonable sensitivity and speciﬁcity.
We believe the diagnoses of TT in both populations to be sufﬁciently
supported by follow-up imaging and, in a signiﬁcant proportion of pa-
tients, cardiacMRI. This point is of critical importance in studies seeking
to establish discriminatory parameters between TT and MI patients.
Furthermore, clinical characteristics (age, sex, ballooning pattern, pres-
ence of bystander coronary artery disease) of our TT populations are
comparable to those of larger trials [7]. Our ﬁndings also suggest an
increase (12/year in the retrospective phase versus 15.8/year in the pro-
spective phase) in the diagnosis of TT as previously described [1,3].
This was an observational clinical study. Notwithstanding, it may
give some insights into themechanisms behind cell death in TT. Indeed,
our data suggest that cell death in TT is different to that ofMI. This is alsoPlease cite this article as: C. Pirlet, et al., Ratio of high-sensitivity troponi
http://dx.doi.org/10.1016/j.ijcard.2017.05.107supported by histological studieswhich show contraction band necrosis
similar to that observed inmyocardial stunning following subarachnoid
haemorrhage or in ischemia-reperfusion syndromes [16]. This is in con-
trast to the coagulation necrosis observed inMI.Moreover, fundamental
studies on rats by Paur et al. [17] suggest that catecholamine toxicity
may be the dominant process. In that case, the kinetics of cardiac
biomarker leakage in TT may be different to those of cardiomyocyte
necrosis in MI.
In contrast to previous reports concerning conventional troponin
[7,11], hs-TnT values were not signiﬁcantly different between groups,
even at peak values. We believe that the progression of hs-TnT and
CKMB in our MI populations may have been blunted by the fact that
only blood samples drawn prior to PCI were taken into account. Thus,
peak troponin values are probably underestimated, especially in the
STEMI groups.
It is well known that CKMB values drop earlier than troponin values
after MI [18]. Therefore, the longer the delay after the beginning of the
event, especially after peak CKMB values, the higher the ratio of
hs-TnT to CKMB. This may mitigate the difference in hs-TnT ratios
between TT and MI. With this concept in mind, we took great care not
to include patients with MI presenting late (N36 h) after symptom
onset. The lesser AUC values at the peak troponin time compared to
admission are consistent with this hypothesis. Our intent in recording
serial hs-TnT and CKMB samples in individual patients was to capture
these values at varying time lapses after the onset of the event. This is
of importance as the delay between the onset of TT and admission is
often unknown and variable.
We performed post-hoc analyses of the delays from symptom onset
to the ﬁrst biomarker sample in both our populations. As speciﬁed
above, the onset of symptoms in TT is sometimes unclear so data were
not always available. Nevertheless, in the retrospective phase, TT
patients presented signiﬁcantly later than MI patients. This difference
in presentation delays begs the questionwhether the statistically signif-
icant differences between our MI populations and TT populations could
simply be explained by different times from symptomonset to biomark-
er analysis. Thus, we compared the tertile of early TT presenters withn to creatine kinase-MB in takotsubo syndrome, Int J Cardiol (2017),
Fig. 2. ROC curves for the hs-TnT/CKMB ratio. Upper left – on admission in the retrospective study. AUC 0.796; 95% CI: 0.71–0.89. Upper right – at the sample time when hs-TnT is at its
peak, in the retrospective study. AUC 0.76; 95% CI: 0.67–0.85. Lower left – on admission in the prospective study. AUC 0.88; 95% CI: 0.83–0.94; comparedwith the ROC curve for the ratio of
NT-proBNP to hs-TnT (peak value) in the prospective study. Lower right – at the sample time when hs-TnT is at its peak, in the prospective study. AUC 0.84; 95% CI: 0.77–0.9. AUC: area
under the curve. CI: conﬁdence interval. CKMB: myocardial fraction of creatine kinase. hs-TnT: high-sensitivity troponin T. ROC: receiver operator characteristic.
5C. Pirlet et al. / International Journal of Cardiology xxx (2017) xxx–xxxthe NSTEMI and STEMI cohorts. The ratio of hs-TnT to CKMB was still
signiﬁcantly higher in this selected population than in myocardial in-
farction patients. Then, we compared the hs-TnT/CKMB ratio amongst
the three tertiles of takotsubo patients (early, intermediate and late
presenters). There were no statistical differences in hs-TnT/CKMB
ratio between these tertiles. Therefore, we consider our observations
to hold true regardless of the delay to presentation in TT patients.
There were no signiﬁcant differences in the interval between symptom
onset and the ﬁrst biomarker sample in the prospective phase. This
discrepancy between the retrospective phase and the prospective phase
is thought to be related to slightly different methodologies, unavailable
data for TT patients with no cardiovascular symptoms and a high preva-
lence of late presenting STEMI patients in this part of the study.
There are some other notable differences in results between the retro-
spective study and the prospective study. These discrepancies are proba-
bly related to random sampling in these relatively small populations.
Graphically, the interquartile range for NSTEMI seems to bewider at
peak values than on admission. This is probably due to the fact that
NSTEMI is a heterogeneous subset of disease encompassing mild
forms that would probably have been classiﬁed as unstable angina
with conventional troponin assays and more severe acute coronary
syndromes with signiﬁcant myocardial necrosis. In this regard, we
acknowledge that NSTEMI patients with minor hs-TnT and no CKMB
elevation displayed high hs-TnT/CKMB ratios. Perhaps, this parameter
should only be calculated in patients with CKMB above the ULN.
Our trial is the ﬁrst to our knowledge to study hs-TnT in TT patients.
This is of importance as high-sensitivity troponin assays are currently
widely used in Europe as recommended in current guidelines of the
European Society of Cardiology [19]. Surprisingly, the revised criteria for
TT include elevation of troponin measured with a conventional assay [6].Please cite this article as: C. Pirlet, et al., Ratio of high-sensitivity troponi
http://dx.doi.org/10.1016/j.ijcard.2017.05.107The clinical presentations of TT and MI bear numerous similarities.
These two entities cannot be differentiated by clinical presentation or
classic diagnostic tools such as ECG and baseline laboratory data.
Epidemiology and risk factor proﬁles may be different but there is
much overlap to the point that bystander non culprit coronary artery
disease is now no longer an exclusion criterion in the diagnosis of TT.
In the setting of ST segment elevation, most will agree that the risk of
denying timely reperfusion therapy through primary PCI outweighs
the risk of occasionally performing invasive imaging in TT. However,
in NSTEMI patients, clinicians are often confronted with difﬁcult clinical
scenarios where echocardiography suggests TT and the decision to
perform coronary angiography may be in question. Thus, adjunctive
discriminators are an interesting concept.
To this end, several parameters have shown reasonable diagnostic
performance. Of these, the ratio of BNP or NT-proBNP to troponin has
been extensively studied [9,10,13,15]. Of note, two of these studies only
compared TT with STEMI patients in whom management would not be
altered on the basis of biomarkers which are often available only after
coronary angiography. Looi et al. [20] showed the utility of analysing
two ECG markers, namely the number of leads with T-wave inversion
and peak T-wave inversion N3 mm, on the second day after admission.
The product of peak troponin I to ejection fraction has also proved to be
a potent discriminator (accuracy 91%) with STEMI patients [21]. Desmet
et al. [22] showed that the presence of an “apical nipple sign” on left
ventriculography provided 100% speciﬁcity for the diagnosis of TT (in
comparison to STEMI patients).More recently, Ghadri et al. [23] published
the Inter-TAK Diagnostic Score which is based on the largest TT cohort
ever published. This score assembles clinical and ECG markers.
Further study is required to conﬁrm the diagnostic performance of
the ratio of hs-TnT to CKMB. The clinical utility behind this parametern to creatine kinase-MB in takotsubo syndrome, Int J Cardiol (2017),
6 C. Pirlet et al. / International Journal of Cardiology xxx (2017) xxx–xxxresides in the fact that it is readily available, with baseline blood analy-
ses, within the ﬁrst hour of management. Secondly, the Inter-TAK score
does not integrate laboratory parameters. We believe that adding the
ratio of hs-TnT to CKMB and/or the ratio of BNP to troponin to such a
clinical risk score could enhance its diagnostic performance. Thirdly,
for different reasons, coronary angiography is sometimes performed
late during the clinical course, after resolution of typical WMA. In
these patients, especially those with mild coronary artery disease,
diagnosis and future management are difﬁcult and the ratio of hs-TnT
to CKMB may then offer a retrospective diagnostic utility.
The magnitude of troponin and/or CKMB could also be of value in
ruling out TT. We observed that no TT patient exceeded the thresholds
of 1770 ng/L and 50.7 μg/L for hs-TnT and CKMB respectively. This last
component could also be used in a diagnostic algorithm.
Three patients were excluded because cardiac MRI showed late
gadoliniumenhancement compatiblewithMI (in two cases) ormyocar-
ditis. Like others [6–8], we believe that cardiac MRI should become a
standard of care in the management of TT patients. Once again, correct
diagnosis is important for the management of individual patients but
it also has implications with regards to further research on TT.5. Study limitations
Asides from the fact that this was a single centre trial studying two
relatively small cohorts, themajor limitation of this studywas the selec-
tion of theNSTEMI and STEMI groups in both phases of the trial. As with
any study that requires a convenience sample of patients, the selection
process may introduce bias into the results.
The second limitation regards ascertaining the diagnosis of TT. Few tri-
als have a ﬂawless methodology in this regard. In our study, performing
systematic cardiac MRI in the prospective phase was not possible and
most patients did not have cardiacMRI in the retrospective phase. There-
fore, we resorted to checking follow-up imaging although this may not
exclude patients who experienced other reversible phenomena that
could mimic TT.
Thirdly, no calculations were performed to assess the prospective
sample size.
Fourth, strictly speaking, we did not observe the natural course of
biomarker proﬁles asmost patients in all groups beneﬁted frommedical
therapy.
Fifth, we studied a limited populationwith regards to racial distribu-
tion. All TT patients were Caucasians.
Lastly, we did not make any attempt to match the different study
populations because their respective characteristics have been recognized
as inherently different.6. Conclusion
The two observational studies show a signiﬁcant difference in the
ratio of hs-TnT to CKMB between TT patients and both NSTEMI and
STEMI patients. As such, this readily available parameter yields reason-
able sensitivity and speciﬁcity. Integrating it in a diagnostic score with
other biomarkers may be relevant.
Further research in larger prospective trials is necessary to conﬁrm
our ﬁndings and to determine the diagnostic performance of this
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